Bayer Deal History & Licensing Activity
Bayer is a large pharma headquartered in Germany. Over the past three years, Bayer has been involved in 8 licensing and acquisition transactions, with a primary focus on Small Molecules (5 deals). The company currently has 50 active clinical trials, primarily in Cardiovascular.
Deals (12mo)
4
Active Trials
50
Top Modality
Small Molecules
Focus Area
Cardiovascular
Bayer Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Bayer in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Stivarga (regorafenib) | Grünenthal | Small Molecules | Approved | acquisition | Sep 21, 2026 |
| rinzimetostat | ORIC Pharmaceuticals | Small Molecules | Phase 3 | collaboration | Jul 14, 2026 |
| Long-acting reversible contraceptives (LARC) business | Apollo | Other | Approved | other | Jul 10, 2026 |
| AT-01 (124-Iodine-evuzamitide) / AT-05 | Attralus | Radiopharmaceuticals | Phase 1 | acquisition | Jan 12, 2026 |
Bayer Pipeline Focus
Therapeutic areas and modalities where Bayer is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Bayer Strategic Signals
Key indicators of Bayer's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Bayer Clinical Pipeline
Bayer has 50 active clinical trials across 6 development phases.
16
Unknown
2
Phase 4
2
Not Applicable
11
Phase 1
12
Phase 2
7
Phase 3
See How Your Asset Matches Bayer's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Cardiovascular assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Bayer Licensing & Deal Activity
Bayer is a large pharma company based in Germany that has been actively engaged in licensing transactions across the biopharma landscape. With 8 deals over the past three years, Bayer ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Bayer include Cardiovascular (14 deals and trials), Solid Tumors (11 deals and trials), Oncology (6 deals and trials), and Metabolic (5 deals and trials). In terms of modality, Bayer has shown particular interest in small molecules, small molecules, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Bayer and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Bayer's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.